Survodutide: indexed trial records

This page carries 12 of the 90 records the literature query returned for Survodutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.

Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.

At a glance

Class

Incretin receptor agonists

Receptor targets as recorded

GLP-1 receptor, Glucagon receptor

Records indexed here

12

Records returned by the query

90

Publication years covered

2025–2026

Query retrieved

2026-10-12

Shape of the indexed record set

Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.

Endpoint coverage

Derived record-set tier

Human trial evidence (INFERRED, derived from record counts)
Basis: 6 of 12 indexed records are interventional human trials by their own assigned publication type.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and it does not rank one compound above another.

What the corpus does not carry for this compound

• Identity fields with no source retrieved: uniprot_id, sequence.
• Reported half-life: no source retrieved, so the value reads Unknown.
• Amounts reported in the cited literature: no row recorded.
• Adverse effects reported in the cited literature: no row recorded.
• Long-form mechanism: not written, because no source was read in full.
• Records the query returned that this corpus does not carry: 78.

An absent row records the absence of a retrieved report, never the absence of the thing itself.

Application register

A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.^[2]

Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.

The records

Where this page sits

Receptor targets

• GLP-1 receptor: every compound in scope acting at it
• Glucagon receptor: every compound in scope acting at it

All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.

Review status

Review tier

High impact

State

Pending qualified review

Compiled by

automated pipeline

Qualified clinical review

None on record

Why this tier was assigned

• 6 indexed record(s) are interventional human trials
• the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus

Checks the pipeline performed

• every cited source id resolves to a sources[] row on the entity
• every identifier is a well-formed PMID or DOI
• study model derived only from assigned MeSH headings and publication types
• banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
• unknown values render as the literal word Unknown

Checks the pipeline did not perform

• no full text was read
• no clinical appraisal of any study
• no assessment of whether the indexed set is representative of the literature

A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.

Sources

1. PubChem Compound Summary for CID 171378821, survodutide. PubChem, National Library of Medicine (2026). pubchem:171378821
2. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:survodutide
3. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular metabolism (2022). pmid:36356832
4. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism (2023). pmid:36527386
5. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity. Diabetes, obesity & metabolism (2023). pmid:36974349
6. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The lancet. Diabetes & endocrinology (2024). pmid:38330987
7. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England journal of medicine (2024). pmid:38847460
8. Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2024). pmid:38095657
9. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. Journal of hepatology (2024). pmid:38857788
10. Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine (2026). pmid:42253238
11. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Obesity (Silver Spring, Md.) (2025). pmid:39495965
12. Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC. Heart failure (2024). pmid:39453356